Page 133 - Read Online

Page 36 Melnik et al. J Transl Genet Genom 2022;6:1-45 https://dx.doi.org/10.20517/jtgg.2021.37

361. Wright ME, Albanes D, Moser AB, et al. Serum phytanic and pristanic acid levels and prostate cancer risk in Finnish smokers.
Cancer Med 2014;3:1562-9. DOI PubMed PMC
362. Xu J, Thornburg T, Turner AR, et al. Serum levels of phytanic acid are associated with prostate cancer risk. Prostate 2005;63:209-14.
DOI PubMed
363. Thornburg T, Turner AR, Chen YQ, Vitolins M, Chang B, Xu J. Phytanic acid, AMACR and prostate cancer risk. Future Oncol
2006;2:213-23. DOI PubMed
364. Hellgren LI. Phytanic acid--an overlooked bioactive fatty acid in dairy fat? Ann N Y Acad Sci 2010;1190:42-9. DOI PubMed
365. Nóbrega M, Cilião HL, Souza MF, et al. Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients
with prostate cancer. Genet Mol Biol 2020;43:e20180329. DOI PubMed PMC
366. Kotova ES, Savochkina YA, Doludin YV, et al. Identification of clinically significant prostate cancer by combined PCA3 and
AMACR mRNA detection in urine samples. Res Rep Urol 2020;12:403-13. DOI PubMed PMC
367. Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre
stage. FEBS J 2008;275:1089-102. DOI PubMed
368. Kuefer R, Varambally S, Zhou M, et al. α-Methylacyl-CoA Racemase: expression levels of this novel cancer biomarker depend on
tumor differentiation. Am J Pathol 2002;161:841-8. DOI PubMed PMC
369. Rubin MA, Bismar TA, Andrén O, et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is
associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev
2005;14:1424-32. DOI PubMed
370. Barry M, Dhillon PK, Stampfer MJ, et al. α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health
Study and Health Professionals Follow-up Study. Prostate 2012;72:301-6. DOI PubMed PMC
371. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alpha-methylacyl-CoA racemase (AMACR) expression in normal
prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate
2005;63:341-6. DOI PubMed
372. Zha S, Ferdinandusse S, Denis S, et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate
cancer. Cancer Res 2003;63:7365-76. PubMed
373. Maruyama K, Oshima T, Ohyama K. Exposure to exogenous estrogen through intake of commercial milk produced from pregnant
cows. Pediatr Int 2010;52:33-8. DOI PubMed
374. Goyon A, Cai JZ, Kraehenbuehl K, Hartmann C, Shao B, Mottier P. Determination of steroid hormones in bovine milk by LC-
MS/MS and their levels in Swiss Holstein cow milk. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2016;33:804-
16. DOI PubMed
375. Malekinejad H, Scherpenisse P, Bergwerff AA. Naturally occurring estrogens in processed milk and in raw milk (from gestated
cows). J Agric Food Chem 2006;54:9785-91. DOI PubMed
376. Tso J, Aga DS. A systematic investigation to optimize simultaneous extraction and liquid chromatography tandem mass spectrometry
analysis of estrogens and their conjugated metabolites in milk. J Chromatogr A 2010;1217:4784-95. DOI PubMed
377. Kolok AS, Ali JM, Rogan EG, Bartelt-Hunt SL. The fate of synthetic and endogenous hormones used in the US beef and dairy
industries and the potential for human exposure. Curr Environ Health Rep 2018;5:225-32. DOI PubMed
378. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-9. DOI PubMed
PMC
379. Bandini M, Gandaglia G, Briganti A. Obesity and prostate cancer. Curr Opin Urol 2017;27:415-21. DOI PubMed
380. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab
1979;48:633-8. DOI PubMed
381. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911.
DOI PubMed
382. Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR. Estrogens and prostate cancer. Prostate Cancer Prostatic
Dis 2019;22:185-94. DOI PubMed
383. Sehgal PD, Bauman TM, Nicholson TM, et al. Tissue-specific quantification and localization of androgen and estrogen receptors in
prostate cancer. Hum Pathol 2019;89:99-108. DOI PubMed PMC
384. Tong da Y, Wen XQ, Jin Y, et al. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells
treated with sex hormones and flutamide. Asian Pac J Cancer Prev 2010;11:1805-9. PubMed
385. Tong da Y, Wu Xy, Sun Hy, Jin Y, Liu Zw, Zhou Fj. Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer
cells treated with sexual hormones and flutamide. Tumour Biol 2012;33:2151-8. DOI PubMed
386. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer.
Eur Urol 2009;55:533-42. DOI PubMed
387. Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate
2018;78:2-10. DOI PubMed
388. Yu Z, Gao W, Jiang E, et al. Interaction between IGF-IR and ER induced by E2 and IGF-I. PLoS One 2013;8:e62642. DOI PubMed
PMC
389. Lanzino M, Morelli C, Garofalo C, et al. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr
Cancer Drug Targets 2008;8:597-610. DOI PubMed
390. Hawsawi Y, El-Gendy R, Twelves C, Speirs V, Beattie J. Insulin-like growth factor - oestradiol crosstalk and mammary gland
tumourigenesis. Biochim Biophys Acta 2013;1836:345-53. DOI PubMed